Chemical structure of molecule repotrectinib (TPX-0005)

oral, CNS-penetrant TRK(A-C) kinase inhibitor

Ph. II candidate for solid tumors (160 mg QD)

from literature starting point

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, CA

The Turning Point Therapeutics oral, brain-penetrant ALK/ROS1/TRK kinase inhibitor, repotrectinib (TPX-0005), is a macrocyclic molecule with a small size intended to limit adverse interactions with resistance mutation hotspots near kinase active…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.